9.17
-2.03%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Keros Therapeutics
From its filings with the US Securities and Exchange Commission
Keros Therapeutics is based in Lexington, Massachusetts. Its shares trade on Nasdaq under the ticker KROS. The SEC classifies its business as pharmaceutical preparations. In the fiscal year to 31 December 2025, it reported revenue of $243.9m and net income of $87.0m. At that date it held total assets of $338.0m and shareholders' equity of $303.1m. By business, License revenue brought in 84.2% of revenue, followed by Service revenue at 15.8%.
We are a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta, or TGF-ß, family of proteins. We are a leader in understanding the role of the TGF-ß family of proteins, which are master regulators of the growth, repair and maintenance of a number of tissues, including skeletal muscle, bone, adipose, heart tissue and blood. By leveraging this understanding, we have discovered and are developing protein therapeutics that have the potential to provide meaningful and potentially disease-modifying benefit to patients. Our lead product candidate, rinvatercept (KER-065), is being developed for the treatment of neuromuscular diseases. Our most advanced product candidate, elritercept (KER-050), is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis. In December 2024, we entered into an exclusive license agreement with Takeda Pharmaceuticals U.S.A., Inc., or Takeda, to further develop, manufacture and commercialize elritercept worldwide outside of mainland China, Hong Kong and Macau, which became effective on January 16, 2025.
Quoted from its 10-K, filed 4 Mar 2026. Read the filing on SEC.gov ↗
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 8 Apr 2020
- Employees
- 78
- Website
- kerostx.com ↗
- Head office
- 1050 WALTHAM STREET, SUITE 302, LEXINGTON, MA, 02421
- Classification
- Pharmaceutical Preparations
- Filer status
- Non-accelerated filer<br>Smaller reporting company
Leadership
Pay as last reported
- Mr. Jean-Jacques BienaimeIndependent Chairman of the Board$652,933
- Dr. Jasbir SeehraPresident, Chief Executive Officer, Director, since 2015$6.3m
- Mr. Keith RegnanteChief Financial Officer$2.3m
- Dr. Lorena LernerChief Scientific Officer
- Mr. Nima FarzanIndependent Director$373,599
- Dr. Carl GordonIndependent Director$386,387
- Dr. Mary GrayIndependent Director$382,099
- Mr. Tomer KarivIndependent Director$396,099
- Mr. Julius KnowlesIndependent Director$373,599
- Mr. Ran NussbaumIndependent Director$367,099
- Dr. Alpna SethIndependent Director$368,811
- Mr. Justin FrantzHead of Investor Relations, since 2022
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 49
- Environment
- 53
- Social
- 52
- Governance
- 42
- Carbon reduction policy
- No
- Human rights policy
- No
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Keros Therapeutics Inc has several key strengths that contribute to its competitive advantage:
Weaknesses
- Despite its strengths, Keros Therapeutics Inc also faces certain weaknesses that may hinder its growth:
Opportunities
- Keros Therapeutics Inc can capitalize on the following opportunities to further enhance its business:
Threats
- Keros Therapeutics Inc should be wary of the following threats that could impact its business:
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.